LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial in the United States for its NTS071, a novel small molecule allosteric reactivator targeting p53 Y220C mutation. NTS071 is ...

神经母细胞瘤（NB）中野生型 p53 的细胞质隔离机制不明。研究人员探究 TSPYL5 在其中的作用，发现 TSPYL5 通过 G3BP1/RanBP2 促进 p53 sumoylation，增强其核输出，增加 NB 细胞恶性特征，为 NB 治疗提供新方向。 在儿童癌症的世界里，神经母细胞瘤（NB）是一个可怕的 ...

Dnmt3a R878H/+ cells have a global hypomethylation phenotype and growth advantage over wild type cells. Following γ-irradiation, Dnmt3a R878H/+ mice show accelerated development of thymic T-cell ...

本文聚焦天然产物在癌症治疗中靶向 p53 的研究。p53 作为肿瘤抑制蛋白（野生型 p53（wt-p53）），突变（mut p53）后会促进癌症发展。文中梳理了多种调节 p53 的天然产物，为癌症治疗研究提供了丰富思路，极具科研价值。 引言 天然产物在药物研发中意义重大 ...

Sustained reactivation of mutant p53 drives durable anti-tumor activity across models, including KRAS co-mutant tumors FMC-220 selectively stabilizes p53 Y220C at lower doses, overcoming key ...